Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 8/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020984 | 1.00 | MEN1 (0.43) | MEN1TTRALBKMT2AGRM5 | |
| SCHEMBL504640 | 0.82 | TTR (0.52) | MEN1TTRALBKMT2AVCAM1 | |
| SCHEMBL633226 | 0.82 | TSHR (0.50) | MEN1TTRALBKMT2AGRM5 | |
| SCHEMBL200313 | 0.82 | TTR (0.52) | MEN1TTRALBKMT2AVCAM1 | |
| SCHEMBL5852713 | 0.82 | VCAM1 (0.43) | MEN1TTRALBKMT2AGRM5 | |
| SCHEMBL2945314 | 0.76 | TSHR (0.32) | — | |
| SCHEMBL21313408 | 0.76 | MMP3 (0.44) | GRM5MAOAMAOB | |
| SCHEMBL16950941 | 0.73 | TTR (0.44) | MEN1TTRALBKMT2AVCAM1 | |
| SCHEMBL114694 | 0.73 | — | — | |
| SCHEMBL151031 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260085063-A1 | BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | UNIV RUTGERS (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4594308-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | Vividion Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009149135-A1 | BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-7381856-B2 | Carbon-carbon cross coupling catalyzed by transition metals on solid supports | WYETH (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1687282-A2 | CARBON-CARBON CROSS COUPLING CATALYZED BY TRANSITION METALS ON SOLID SUPPORTS | Wyeth (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050137438-A1 | Carbon-carbon cross coupling catalyzed by transition metals on solid supports | WYETH (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005051869-A2 | CARBON-CARBON CROSS COUPLING CATALYZED BY TRANSITION METALS ON SOLID SUPPORTS | WYETH (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | MEN1 1555/4885TTR 3982/4885ALB 4493/4885 |
| US-20050137438-A1 | Carbon-carbon cross coupling catalyzed by transition metals on solid supports | SMARCC2, SMARCC1, SCO2 | MEN1 783/4885TTR 2841/4885ALB 2556/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | MEN1 2848/4885TTR 3135/4885ALB 3875/4885 |
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | XDH, PRDX5, CYP4X1 | MEN1 4307/4885TTR 2799/4885ALB 3765/4885 |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | MEN1 2304/4885TTR 3587/4885ALB 4328/4885 |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | MEN1 3883/4885TTR 2662/4885ALB 4174/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | MEN1 1819/4885TTR 171/4885ALB 357/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | MEN1 2120/4885TTR 122/4885ALB 1330/4885 |
| US-20260085063-A1 | BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ACE2, CTRL, CTSL | MEN1 4054/4885TTR 1440/4885ALB 895/4885 |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | MEN1 818/4885TTR 4056/4885ALB 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.